Indivior PLC (INDV)
NASDAQ: INDV · Real-Time Price · USD
35.80
+0.26 (0.73%)
Dec 19, 2025, 10:33 AM EST - Market open
Indivior Revenue
Indivior had revenue of $314.00M in the quarter ending September 30, 2025, with 2.28% growth. This brings the company's revenue in the last twelve months to $1.18B, down -0.25% year-over-year. In the year 2024, Indivior had annual revenue of $1.19B with 8.69% growth.
Revenue (ttm)
$1.18B
Revenue Growth
-0.25%
P/S Ratio
3.77
Revenue / Employee
$1,122,740
Employees
1,051
Market Cap
4.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.19B | 95.00M | 8.69% |
| Dec 31, 2023 | 1.09B | 192.00M | 21.31% |
| Dec 31, 2022 | 901.00M | 110.00M | 13.91% |
| Dec 31, 2021 | 791.00M | 144.00M | 22.26% |
| Dec 31, 2020 | 647.00M | -138.00M | -17.58% |
| Dec 31, 2019 | 785.00M | -220.00M | -21.89% |
| Dec 31, 2018 | 1.01B | -88.00M | -8.05% |
| Dec 31, 2017 | 1.09B | 35.00M | 3.31% |
| Dec 31, 2016 | 1.06B | 44.00M | 4.34% |
| Dec 31, 2015 | 1.01B | -101.00M | -9.06% |
| Dec 31, 2014 | 1.12B | -101.00M | -8.31% |
| Dec 31, 2013 | 1.22B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
INDV News
- 1 day ago - New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations - PRNewsWire
- 4 weeks ago - Indivior Concludes Legacy U.S. Department of Justice Matter - PRNewsWire
- 4 weeks ago - Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference - PRNewsWire
- 6 weeks ago - Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine - PRNewsWire
- 7 weeks ago - Indivior PLC (INDV) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance - PRNewsWire
- 7 weeks ago - Indivior to Participate in the Stifel 2025 Healthcare Conference - PRNewsWire
- 2 months ago - Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th - PRNewsWire